ArticlePLoS neglected tropical diseases2025
Epidemiology of ovale, vivax and falciparum malaria in the highlands of Cameroon: An integrated community survey of human infection and vector abundance.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatial and temporal inequalities in malaria incidence and mortality among children aged 0-4 years in Somalia: a subnational analysis, 2010-2019.Tropical medicine and health · 2026Article
- Complex non-Research square · 2026Article
- Mixed malaria infections: A critical review and Detect-Characterise-Act surveillance framework.Current research in parasitology & vector-borne diseases · 2026Review
Corrections and comments
- Update of
Authors and funding
28 authors.
Funding
Abstract
Despite global malaria control efforts, the disease caused 263 million cases and 597,000 deaths in 2023. While Plasmodium falciparum accounts for most cases in Africa, non-falciparum species, such as P. ovale spp. and P. vivax, can cause relapse infections and are increasingly recognized as significant contributors to human disease. In particular, the highlands of West Cameroon have previously been reported to have high P. vivax infection rates. This study presents preliminary results from the Relapsing Malaria in Africa (ReMA) study, conducted in Dschang, Cameroon, to assess the prevalence and epidemiology of P. vivax and P. ovale spp. A cross-sectional survey of 3,661 participants from 871 households across seven health areas identified a low prevalence of P. vivax (0.1%) and P. ovale spp. (0.64%) using quantitative real time PCR (qPCR), while P. falciparum remained prevalent at 8.1%. Co-infections of P. ovale spp. with P. falciparum were observed in 23.1% of P. ovale spp. cases. While gametocytemia was common among falciparum infections, leveraging a new ovale gametocyte assay, we found that gametocytemia was uncommon among the qPCR- positive ovale infections. Spatial analysis found P. vivax and P. ovale spp. infections concentrated in Penka-Michel and Baleveng, the former having higher Anopheles spp. abundance than other areas assessed. Risk factor analysis revealed children and those with recent domestic travel had higher odds of P. falciparum infection, but no significant associations were found for P. ovale spp. infections. Entomological surveys confirmed high densities of Anopheles gambiae sensu lato (s.l.) and An. funestus (s.l.), with significantly higher human landing capture rates for An. gambiae s.l compared to other mosquito species. While these findings suggest that the malaria species which cause relapse are not as widespread as previously thought in West Cameroon, understanding factors driving their persistent transmission, especially without prevalent gametocytemia, will be important for disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.